TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15121645

Group type: EXPERIMENTAL
Intervention: Short-term dynamic psychotherapy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 50
Study: 11421838

Group type: EXPERIMENTAL
Intervention: Ultrasound examination of the spinal region prior to epidural puncture
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard loss of resistance technique (control group)
Number of subjects: 72
Study: 9508174

Group type: EXPERIMENTAL
Intervention: i.t. methotrexate (MTX) and cranial radiation therapy (CRT) (regimen A, n = 317)
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: intensified i.t. methotrexate alone (regimen B, n = 319)
Number of subjects: 636

Group type: COMPARATOR
Intervention: Comparison of regimen A and regimen B
Number of subjects: 636
Study: 9419751

Group type: EXPERIMENTAL
Intervention: DHEA infusion (1 mg/hour for 17 hours)
Number of subjects: 5
Study: 3354444

Group type: EXPERIMENTAL
Intervention: Caffeine (3.3 mg/kg, equivalent to 2 to 3 cups of coffee)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8420868

Group type: EXPERIMENTAL
Intervention: Misonidazole combined with radiation therapy
Number of subjects: 779

Group type: EXPERIMENTAL
Intervention: Cranial treatment responders
Number of subjects: 779

Group type: EXPERIMENTAL
Intervention: Patients with <= 3 lesions
Number of subjects: 779

Group type: EXPERIMENTAL
Intervention: Patients with favorable clinical characteristics (age <= 60, KPS >= 70, primary lesion absent or controlled, brain as sole site of metastasis)
Number of subjects: 779
Study: 321177

Group type: EXPERIMENTAL
Intervention: Naproxen (300 or 600 mg)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Naproxen sodium (275 mg)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Aspirin (650 mg)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Codeine (60 mg)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study: 31736077

Group type: EXPERIMENTAL
Intervention: Morus nigra L. (MN) leaf powder 250 mg for 60 days
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT) 1 mg estradiol for 60 days
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo for 60 days
Number of subjects: 62
Study: 29897622

Group type: EXPERIMENTAL
Intervention: Parent education program consisting of six 2.5-hour sessions
Number of subjects: 56

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 56
Study: 28680091

Group type: EXPERIMENTAL
Intervention: Micronized granular powder (GP) of Salvia miltiorrhiza (SM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional decoction (TD) of Salvia miltiorrhiza (SM)
Number of subjects: 0
Study: 25586298

Group type: EXPERIMENTAL
Intervention: ropinirole prolonged release (PR) administered for 24 weeks as adjunctive to levodopa
Number of subjects: 295
Study: 23884830

Group type: EXPERIMENTAL
Intervention: Extra-virgin olive oil enriched with antioxidants
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Extra-virgin olive oil enriched with probiotics
Number of subjects: 8
Study: 21740570

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine phosphate-trimethoprim (DPT)
Number of subjects: 418

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 418
Study: 19824601

Group type: EXPERIMENTAL
Intervention: Double-incision technique
Number of subjects: 40
Study: 16708725

Group type: COMPARATOR
Intervention: Metal matrix and wooden wedge
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Polyester matrix and reflective wedge
Number of subjects: 23
Study: 15636080

Group type: EXPERIMENTAL
Intervention: Implementation of WHO/UNICEF Breastfeeding Hospital Initiative (BFHI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breastfeeding support groups activity (1999-2000)
Number of subjects: 0
Study: 11419238

Group type: EXPERIMENTAL
Intervention: 8% sevoflurane
Number of subjects: 20
Study: 9847819

Group type: EXPERIMENTAL
Intervention: Osteoporosis prevention program
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 31
Study: 7980764

Group type: EXPERIMENTAL
Intervention: Anterior myocardial infarction
Number of subjects: 2466

Group type: COMPARATOR
Intervention: Nonanterior myocardial infarction
Number of subjects: 2466
Study: 2599475

Group type: EXPERIMENTAL
Intervention: melphalan with Corynebacterium parvum
Number of subjects: 186

Group type: COMPARATOR
Intervention: melphalan without Corynebacterium parvum
Number of subjects: 186
Study: 30589922

Group type: EXPERIMENTAL
Intervention: Dexamethasone implant after switching from aflibercept
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Aflibercept after switching from bevacizumab
Number of subjects: 49
Study: 28270173

Group type: EXPERIMENTAL
Intervention: PEG + Probiotic Mixture (PM)
Number of subjects: 55

Group type: COMPARATOR
Intervention: PEG only
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: PEG + PM
Number of subjects: 55
Study: 25695576

Group type: EXPERIMENTAL
Intervention: Perioperative smoking cessation intervention (brief counseling, brochures, referral to quitline, 6-week transdermal nicotine replacement)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 168
Study: 23263458

Group type: EXPERIMENTAL
Intervention: 0.4 g/kg alcohol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.8 g/kg alcohol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21525768

Group type: EXPERIMENTAL
Intervention: Synbiotics (1 g of Bifidobacterium breve strain Yakult three times a day and 5.5 g of GOS once a day for one year)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Synbiotics
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (no synbiotics)
Number of subjects: 41
Study: 17892374

Group type: EXPERIMENTAL
Intervention: Zoledronic acid 5 mg intravenously once yearly
Number of subjects: 7736

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7736
Study: 16490030

Group type: EXPERIMENTAL
Intervention: Aggressive diabetes mellitus treatment and good glycemic control
Number of subjects: 25
Study: 12859608

Group type: EXPERIMENTAL
Intervention: Open kinetic chain tonification exercises (group I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Closed kinetic chain tonification exercises (group II)
Number of subjects: 60
Study: 11228790

Group type: EXPERIMENTAL
Intervention: Anxiolytic premedication (midazolam 7.5 mg, midazolam 15 mg, diazepam 15 mg)
Number of subjects: 1263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1263
Study: 9931829

Group type: EXPERIMENTAL
Intervention: Cephalograde tibial nail
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plate osteosynthesis
Number of subjects: 0
Study: 8044953

Group type: COMPARATOR
Intervention: Intensive vascular training alone
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Intravenous pentoxifylline (200 mg over 2 hours BID) with intensive vascular training
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Intravenous prostaglandin E1 (40 micrograms over 2 hours BID) with intensive vascular training
Number of subjects: 44

Group type: COMPARATOR
Intervention: Follow-up for all groups after 1 year
Number of subjects: 44
Study: 2647319

Group type: EXPERIMENTAL
Intervention: Duplex scanning
Number of subjects: 47
Study: 30755171

Group type: EXPERIMENTAL
Intervention: Modified full enteral nutrition (standard full EN in conjunction with prokinetic drug)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Permissive underfeeding (40 to 60% of estimated caloric requirements)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Standard full enteral nutrition (advancement to target nutrition goals)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: All interventions (modified full EN, permissive underfeeding, standard full EN)
Number of subjects: 600
Study: 28364415

Group type: EXPERIMENTAL
Intervention: Oscillating white noise at 12 Hz (targeting slow spindles)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oscillating white noise at 15 Hz (targeting fast spindles)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Constant white noise (50 Hz control condition)
Number of subjects: 0
Study: 26482384

Group type: EXPERIMENTAL
Intervention: High-Intensity Exercise (HIE)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Moderate-Intensity Exercise (MIE)
Number of subjects: 47
Study: 25163498

Group type: EXPERIMENTAL
Intervention: 30 g of roasted flaxseed powder for 3 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (similar dietary guidelines)
Number of subjects: 50
Study: 23095069

Group type: EXPERIMENTAL
Intervention: Professional oral health care (POHC) treatment by dental hygienists (n = 21)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (n = 19)
Number of subjects: 40
Study: 19380445

Group type: EXPERIMENTAL
Intervention: PCI(10) and PCI(20) - combination of CP-751,871 (10 to 20 mg/kg), paclitaxel (200 mg/m²), and carboplatin (AUC 6) every 3 weeks for up to six cycles.
Number of subjects: 156

Group type: COMPARATOR
Intervention: PC - paclitaxel and carboplatin alone.
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: PCI(20) - nonrandomized single-arm cohort of 30 patients with nonadenocarcinoma tumor histology.
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: PCI with squamous cell carcinoma histology.
Number of subjects: 156

Group type: COMPARATOR
Intervention: CP-751,871 after disease progression in PC group.
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: PCI(20)/PC hazard ratio for progression-free survival.
Number of subjects: 156
Study: 17447178

Group type: EXPERIMENTAL
Intervention: Guideline exposed physicians
Number of subjects: 1319

Group type: COMPARATOR
Intervention: Control group (guideline naive physicians)
Number of subjects: 1319
Study: 15173031

Group type: EXPERIMENTAL
Intervention: Amoxicillin prophylaxis
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 11965280

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation with measles vaccine
Number of subjects: 0
Study: 10453786

Group type: EXPERIMENTAL
Intervention: Ankle-arm index (AAI) less than 1.0
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Ankle-arm index (AAI) greater than 1.0
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Ankle-arm index (AAI)
Number of subjects: 62
Study: 7874633

Group type: EXPERIMENTAL
Intervention: Noncemented total hip replacement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cemented total hip replacement
Number of subjects: 0
Study: 2219758

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Aspirin with dipyridamol
Number of subjects: 266

Group type: COMPARATOR
Intervention: 5% dextrose (Control)
Number of subjects: 266
Study: 341337

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 950

Group type: COMPARATOR
Intervention: Piperazine citrate
Number of subjects: 950

Group type: COMPARATOR
Intervention: Pyrantel pamoate
Number of subjects: 950

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 950
Study: 31784354

Group type: EXPERIMENTAL
Intervention: 50 mg amisulpride (MDDAmisulpride)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (MDDPlacebo)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (HCPlacebo)
Number of subjects: 31
Study: 30919377

Group type: EXPERIMENTAL
Intervention: taTME
Number of subjects: 107

Group type: COMPARATOR
Intervention: Laparoscopic TME
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 107
Study: 28423174

Group type: EXPERIMENTAL
Intervention: Propranolol (2 mg/kg/d) for 16 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Steroid (2 mg/kg/d) for 16 weeks
Number of subjects: 34
Study: 25668220

Group type: EXPERIMENTAL
Intervention: PLUNGE intervention (n = 97 students)
Number of subjects: 168

Group type: COMPARATOR
Intervention: 7-week wait-list control (n = 71 students)
Number of subjects: 168
Study: 23390999

Group type: EXPERIMENTAL
Intervention: Deep hypothermic circulatory arrest (DHCA)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Continuous antegrade cerebral perfusion (ACP)
Number of subjects: 12
Study: 21549518

Group type: EXPERIMENTAL
Intervention: 50.4 Gy
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: 64.8 Gy
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Co-deletion of 1p19q
Number of subjects: 203
Study: 19766812

Group type: EXPERIMENTAL
Intervention: Medtronic Mosaic (MM) porcine valve
Number of subjects: 152

Group type: COMPARATOR
Intervention: Edwards Perimount (EP) bovine valve
Number of subjects: 152
Study: 17701638

Group type: EXPERIMENTAL
Intervention: Integrated teaching session on clinical decision analysis
Number of subjects: 132

Group type: COMPARATOR
Intervention: Surgical rotations (control)
Number of subjects: 132
Study: 15579519

Group type: EXPERIMENTAL
Intervention: Erythropoietin treatment
Number of subjects: 2696

Group type: EXPERIMENTAL
Intervention: Higher hemoglobin targets (> 130 g/L)
Number of subjects: 2696

Group type: COMPARATOR
Intervention: Lower hemoglobin targets (< 120 g/L)
Number of subjects: 2696
Study: 11179530

Group type: EXPERIMENTAL
Intervention: Quinapril treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no quinapril treatment)
Number of subjects: 0
Study: 9672506

Group type: EXPERIMENTAL
Intervention: Home-based nutrition education program
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Standard nutrition counseling
Number of subjects: 261

Group type: COMPARATOR
Intervention: At-risk control group
Number of subjects: 261
Study: 9751014

Group type: EXPERIMENTAL
Intervention: Consensus IFN‐alpha 3 micrograms (n = 232 patients)
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: IFN‐alpha 2b 3 million units (n = 240 patients)
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: End-of-treatment HCV RNA response
Number of subjects: 704
Study: 1884902

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) treatment for a mean of 13.8 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Former CsA patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) treatment
Number of subjects: 0
Study: 6356856

Group type: EXPERIMENTAL
Intervention: Trimazosin
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 96
Study: 30958508

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (15 mg per day)
Number of subjects: 7112

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 7112
Study: 28125095

Group type: EXPERIMENTAL
Intervention: Lactoferrin concentration in colostrum
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Lactoferrin concentration in transitional milk
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Lactoferrin concentration at 1 month postpartum
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Lactoferrin concentration at 2 months postpartum
Number of subjects: 346

Group type: COMPARATOR
Intervention: Comparison of LF concentration across stages of lactation
Number of subjects: 346

Group type: COMPARATOR
Intervention: Association of maternal factors with LF concentration
Number of subjects: 346
Study: 26795413

Group type: EXPERIMENTAL
Intervention: Higher oxygen saturation targeting (91‐95%)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Lower oxygen saturation targeting (85‐89%)
Number of subjects: 38
Study: 24710621

Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 124
Study: 22883004

Group type: EXPERIMENTAL
Intervention: Combined therapy of valproic acid (VPA) and lamotrigine (LTG)
Number of subjects: 134
Study: 20417262

Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 7-valent pneumococcal conjugate vaccine (PCV7)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13) and 7-valent pneumococcal conjugate vaccine (PCV7)
Number of subjects: 0
Study: 18486222

Group type: EXPERIMENTAL
Intervention: Low-intensity laser treatment
Number of subjects: 225

Group type: COMPARATOR
Intervention: Observation (control)
Number of subjects: 225
Study: 15695125

Group type: COMPARATOR
Intervention: Stenting
Number of subjects: 1203

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1203

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1203
Study: 14694970

Group type: EXPERIMENTAL
Intervention: Intracervical PGE2 (dinoprostone 0.5 mg) by gel (n = 66)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Intravaginal PGE2 (dinoprostone 10 mg) by pessary (n = 49)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Both groups (gel and pessary)
Number of subjects: 115
Study: 10649809

Group type: EXPERIMENTAL
Intervention: Nafarelin
Number of subjects: 192

Group type: COMPARATOR
Intervention: Leuprolide
Number of subjects: 192
Study: 9335389

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 2-g treatment group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy (quadruple sequential induction therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 0
Study: 8254147

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluoxetine and Amitriptyline
Number of subjects: 0
Study: 2871486

Group type: EXPERIMENTAL
Intervention: Cyclosporine and prednisone
Number of subjects: 291

Group type: COMPARATOR
Intervention: Control immunosuppressive therapy (azathioprine and prednisone, with or without antilymphocyte globulin)
Number of subjects: 291
Study: 31145180

Group type: COMPARATOR
Intervention: Moderate-intensity double-leg cycling (MCTDL)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: High-intensity double-leg cycling (HITDL)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: High-intensity single-leg cycling (HITSL)
Number of subjects: 53
Study: 30129417

Group type: EXPERIMENTAL
Intervention: Topical simvastatin 1% topical solution
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Oral simvastatin 20mg/day
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 27665525

Group type: COMPARATOR
Intervention: Triple therapy (proton pump inhibitor, amoxicillin 1000mg, clarithromycin 500mg or metronidazole 400mg, given twice daily for 7-14 days)
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Sequential therapy (PPI twice daily for 10 days, amoxicillin 1000mg twice daily for the first 5 days, followed by clarithromycin 500mg and metronidazole 400mg twice daily for the subsequent 5 days)
Number of subjects: 485

Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Sequential therapy
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 485
Study: 25240704

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 199
Study: 22578530

Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention for at-risk drinking (BMI-ETOH) among Hispanics with drug dependence
Number of subjects: 1493
Study: 19394553

Group type: EXPERIMENTAL
Intervention: Low pressure bandages (20-30 mm Hg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: High pressure bandages (44-58 mm Hg)
Number of subjects: 36
Study: 17482716

Group type: EXPERIMENTAL
Intervention: Histopathologic diagnosis by dermatopathologists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histopathologic diagnosis of basal cell carcinoma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histopathologic diagnosis of SCC in the actinic keratosis spectrum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histopathologic diagnosis of invasive SCC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histopathologic diagnosis of SCC in situ
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histopathologic diagnosis of actinic keratosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histopathologic diagnosis of morphea subtype of basal cell carcinoma
Number of subjects: 0
Study: 15302787

Group type: EXPERIMENTAL
Intervention: High-dose sirolimus (24 mg loading dose, 2 mg/d for 7 days)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Usual-dose sirolimus (8 mg loading dose, 2 mg/d for 7 days)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 12241774

Group type: EXPERIMENTAL
Intervention: tirofiban
Number of subjects: 4809

Group type: COMPARATOR
Intervention: abciximab
Number of subjects: 4809
Study: 8123267

Group type: COMPARATOR
Intervention: Thiopental sodium 4 mg/kg i.v., followed by 0.5% to 1.5% enflurane and 67% N2O in O2 (Group 1)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Propofol 2 mg/kg i.v., followed by 0.5% to 1.5% enflurane and 67% N2O in O2 (Group 2)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Propofol 2 mg/kg i.v., followed by propofol 50 to 160 micrograms/kg/min i.v. and 67% N2O in O2 (Group 3)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Enflurane for maintenance of anesthesia
Number of subjects: 61
Study: 3322358

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg, three times daily for 6 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31115667

Group type: EXPERIMENTAL
Intervention: Supervised low-intensity cycling for 20 minutes during chemotherapy infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Usual care during chemotherapy infusion
Number of subjects: 10
Study: 30305142

Group type: COMPARATOR
Intervention: Standard-of-care ART initiation from clinic staff
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Symptom report, medical history, brief physical exam, and readiness assessment with TB module
Number of subjects: 600
Study: 28770525

Group type: EXPERIMENTAL
Intervention: Resourceful Adolescent Program-Autism Spectrum Disorder (RAP-A-ASD)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 29
Study: 26600017

Group type: EXPERIMENTAL
Intervention: Baseline serum magnesium (Mg) increase of 0.1 mmol/L
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Baseline serum magnesium (Mg) levels over time
Number of subjects: 365
Study: 23329358

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy alone
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with total body irradiation
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Patients (combined)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 28